Insitro

Uses AI and automation to industrialize drug discovery and development for rare diseases and cancers.

AI-powered biotechnology company developing RNA therapeutics for genetic diseases.

Shares Biotech, Drug Discovery

AI-driven platform for protein-level disease mapping and drug discovery.

Shares Drug Discovery, Drug Development

Engineering-driven DNA design platform to overcome biological barriers in genetic medicines.

Shares Drug Discovery, Machine Learning

Generative AI for discovering breakthrough medicines by modeling complex biological systems.

Shares Drug Discovery, Biotech

AI-driven drug discovery company developing novel medicines for unmet patient needs.

Shares Biotech, HealthTech

Computational platform using LLMs trained on biological and chemical data for drug discovery.

Shares Drug Discovery, Biotech

While a partner, Bristol Myers Squibb also conducts its own drug discovery and development, including leveraging AI, which could be seen as a competing approach to Insitro's platform-as-a-service model for other clients.

Competing product: Internal R&D and collaborations in drug discovery

Eli Lilly, a partner of Insitro, also develops its own drug discovery platforms like Lilly TuneLab™ that provide biotechs access to machine learning models, creating a competitive offering in the broader market.

Competing product: Lilly TuneLab™ (drug discovery platform)